NEORAL LABELING FOR RHEUMATOID ARTHRITIS RECOMMENDS 16 WEEK TRIAL FOR RESPONSE; MONTHLY MONITORING OF BLOOD PRESSURE, CREATININE LEVELS RECOMMENDED
Executive Summary
Labeling for Novartis' Neoral recommends a four-month trial of therapy to identify a response. "If no benefit is seen by 16 weeks of therapy, Neoral therapy should be discontinued," labeling states.